Difference between revisions of "Insulin"
| Line 38: | Line 38: | ||
|- | |- | ||
| Surface accessibility | | Surface accessibility | ||
| − | | [http://gibk21.bse.kyutech.ac.jp/asaview/all/ | + | | [http://gibk21.bse.kyutech.ac.jp/asaview/all/1ben.pdf ASAView] pdf |
| + | [http://gibk21.bse.kyutech.ac.jp/asaview/all/1ben.txt ASAView] txt | ||
|- | |- | ||
| Disorder prediction | | Disorder prediction | ||
Revision as of 08:20, 25 July 2007
| Template:Infobox header| Insulin | |
|---|---|
| Insulin | |
| Substrate peptide name | Insulin |
| Synonyms | - |
| Determination type | In vitro |
| Source | Homo sapiens |
| Subcellular localization | Extracellular; plasma |
| Swissprot ID | P08865 |
| Reactive glutamines | chain A - Q5, Q15 |
| Reactive lysines | - |
| Substrate sequence | chain A - GIVEQC*C*ASVC*SLYQLENYC*N
chain B - FVNQHLC*GS |
| Structure | 1BEN |
| Surface accessibility | ASAView pdf
ASAView txt |
| Disorder prediction | IUPred |
| Reference | PMID:14342319 |
| Notes | * the Cys residues are oxidized |
| Template:Infobox header | | |
